About Kamui Pharma
Kamui Pharma is a company based in Asahikawa (Japan) founded in 2018.. Kamui Pharma has raised $96.26 million across 2 funding rounds from investors including Cyberdyne, DG Ventures and Mitsubishi UFJ Capital. Kamui Pharma operates in a competitive market with competitors including Aclaris Therapeutics, Novozymes, Phathom Pharmaceuticals, Protagonist Therapeutics and Seed, among others.
- Headquarter Asahikawa, Japan
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$96.26 M (USD)
in 2 rounds
-
Latest Funding Round
$96.26 M (USD), Series B
Jul 26, 2022
-
Investors
Cyberdyne
& 4 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Kamui Pharma
Kamui Pharma has successfully raised a total of $96.26M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $96.26 million completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $96.3M
- First Round First Round
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2022 | Amount | Series B - Kamui Pharma | Valuation | Cyberdyne , DG Ventures | |
| Jun, 2018 | Amount | Seed - Kamui Pharma | Valuation | Mitsubishi UFJ Capital |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Kamui Pharma
Kamui Pharma has secured backing from 5 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Cyberdyne, DG Ventures and Mitsubishi UFJ Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
DG Ventures is engaged in investing in startup companies.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in AI, energy, and various sectors.
|
Founded Year | Domain | Location | |
|
Venture capital investments are made in emerging Japanese companies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Kamui Pharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Kamui Pharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Kamui Pharma Comparisons
Competitors of Kamui Pharma
Kamui Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, Novozymes, Phathom Pharmaceuticals, Protagonist Therapeutics and Seed, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel dermatologic therapies are developed for skin conditions.
|
|
| domain | founded_year | HQ Location |
Biosolutions and enzymes are developed for biotechnology applications across industries.
|
|
| domain | founded_year | HQ Location |
Therapies for gastrointestinal diseases are developed by Phathom Pharmaceuticals.
|
|
| domain | founded_year | HQ Location |
Oral peptide therapeutics are developed for gastrointestinal diseases.
|
|
| domain | founded_year | HQ Location |
Synbiotics are developed for simulating the gut microbiome.
|
|
| domain | founded_year | HQ Location |
Microbiome therapeutics are developed to address diverse diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Kamui Pharma
When was Kamui Pharma founded?
Kamui Pharma was founded in 2018.
Where is Kamui Pharma located?
Kamui Pharma is headquartered in Asahikawa, Japan. It is registered at Asahikawa, Hokkaido, Japan.
Is Kamui Pharma a funded company?
Kamui Pharma is a funded company, having raised a total of $96.26M across 2 funding rounds to date.
What does Kamui Pharma do?
Kamui Pharma was founded in 2018 in Asahikawa, Japan, within the biotechnology sector. Probiotic medicines targeted at gastrointestinal diseases are developed, with a focus on inflammatory bowel disease (IBD). Physiologically active substances derived from probiotics, including poly P from Lactobacillus Brevis, are utilized for treatment purposes. Beneficial functions of these substances have been identified through research operations conducted in the region.
Who are the top competitors of Kamui Pharma?
Kamui Pharma's top competitors include Phathom Pharmaceuticals, Novozymes and Aclaris Therapeutics.
Who are Kamui Pharma's investors?
Kamui Pharma has 5 investors. Key investors include Cyberdyne, DG Ventures, Mitsubishi UFJ Capital, Hokkaido Venture Capital, and Katsutoshi Hirose.